Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Xiaonan, Hong"'
Autor:
Guang‐Liang Chen, Kai Xue, Qunling Zhang, Zu‐guang Xia, Jia Jin, Ran Li, Yizhen Liu, Fangfang Lv, Xiaonan Hong, Xiaoqiu Li, Junning Cao
Publikováno v:
Cancer Medicine, Vol 13, Iss 16, Pp n/a-n/a (2024)
Abstract Background In relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), a negative prognosis is frequently linked to heightened epigenetic heterogeneity. Chidamide, a selective histone deacetylase inhibitor, shows promise as a targe
Externí odkaz:
https://doaj.org/article/2ad1fa44c0184b318107224eea500a7a
Publikováno v:
Heliyon, Vol 10, Iss 5, Pp e26795- (2024)
Objective: The existing Central Nervous System-International Prognostic Index (CNS-IPI) provides insufficient guidance for predicting central nervous system (CNS) relapse in individuals with primary breast diffuse large B-cell lymphoma (DLBCL). This
Externí odkaz:
https://doaj.org/article/e2ec1dfef4fb4d5bb6496816dd600043
Autor:
Jun Zhu, Xiaonan Hong, Yu Qin Song, Brendan Hodkinson, Sriram Balasubramanian, Songbai Wang, Qingyuan Zhang, Yuankai Shi, Huiqiang Huang, Huilai Zhang, Yan Zhu, Stephen Martin Shreeve, Steven Sun, Ze Wang, Xiaocan Wang, Yue Fan, Wyndham Wilson, Jessica Vermeulen
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1154-1164 (2022)
Abstract In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) did no
Externí odkaz:
https://doaj.org/article/c5c60059677a4edd904790870a35470b
Autor:
Jia Jin, Dongmei Ji, Zuguang Xia, Kai Xue, Qunling Zhang, Yizhen Liu, Junning Cao, Xiaonan Hong, Juan J. Gu, Ye Guo, Fangfang Lv
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background R-CHOP with or without radiotherapy is the standard treatment for limited-stage diffuse large B-cell lymphoma (DLBCL). To prevent overtreatment, we assessed whether four cycles of CHOP plus six applications of rituximab was adequa
Externí odkaz:
https://doaj.org/article/fc44627618a64aeda64b0929698afd45
Autor:
Xiaonan Hong, Yuqin Song, Yuankai Shi, Qingyuan Zhang, Wei Guo, Gang Wu, Junmin Li, Jifeng Feng, Anastasiia Kinkolykh, Andrea Knapp, Tongyu Lin, Jing Ni
Publikováno v:
Chinese Medical Journal, Vol 135, Iss 4, Pp 433-440 (2022)
Abstract. Backgrounds:. GALLIUM is a global phase III study that demonstrated significant improvements in progression-free survival (PFS) for obinutuzumab plus chemotherapy (G-chemo) vs. rituximab plus chemotherapy (R-chemo) in previously untreated p
Externí odkaz:
https://doaj.org/article/7de0072420c24d7bace79de349c9e623
Autor:
guangliang Chen, Dou-dou Li, Sufen Sufen, Shiyu Jiang, Qunling Zhang, jia jin, Zuguang Xia, Yizhen Liu, Xiaojian Liu, Yanzhe Zhu, Yu Chen, Lingli Gu, Xiaonan Hong, Junning Cao, Rong Tao, Fangfang Lv
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 14, Iss 1 (2022)
Background Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited data on the clinical features and prognostic factors. Patients and Methods A consecutive cohort of patients with PB-
Externí odkaz:
https://doaj.org/article/ceeddbe48bfe441792810930476f2c20
Autor:
Yizhen Liu, Kai Xue, Zuguang Xia, Jia Jin, Jiachen Wang, Hui Sun, Fangfang Lv, Xiaojian Liu, Junning Cao, Xiaonan Hong, Ye Guo, Xuejun Ma, Qunling Zhang
Publikováno v:
Cancer Medicine, Vol 9, Iss 15, Pp 5400-5405 (2020)
Abstract Background The optimal treatment strategies for extranodal natural killer/ T‐cell lymphoma (ENKTL) have not been defined. We conducted this prospective, open‐label, phase II, single‐center study aimed to explore the efficacy and safety
Externí odkaz:
https://doaj.org/article/626da0d61cb84edbad354efd609c0289
Autor:
Yuankai Shi, Yongping Song, Yan Qin, Qingyuan Zhang, Xiaohong Han, Xiaonan Hong, Dong Wang, Wei Li, Yang Zhang, Jifeng Feng, Jianmin Yang, Huilai Zhang, Chuan Jin, Yu Yang, Jianda Hu, Zhao Wang, Zhengming Jin, Hang Su, Huaqing Wang, Haiyan Yang, Weijun Fu, Mingzhi Zhang, Xiaohong Zhang, Yun Chen, Xiaoyan Ke, Li Liu, Ding Yu, Guo’an Chen, Xiuli Wang, Jie Jin, Tao Sun, Xin Du, Ying Cheng, Pingyong Yi, Xielan Zhao, Chaoming Ma, Jiancheng Cheng, Katherine Chai, Alvin Luk, Eugene Liu, Xin Zhang
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-5 (2020)
Abstract Rituximab in combination with chemotherapy has shown efficacy in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years. HLX01 was developed as the rituximab biosimilar following a stepwise approach to demonstrate biosimi
Externí odkaz:
https://doaj.org/article/9fa40c795d7040e7acb499b265963df7
Autor:
Yizhen Liu, Jinjin Jiang, Lianfang Liu, Zezhou Wang, Baohua Yu, Zuguang Xia, Qunling Zhang, Dongmei Ji, Xiaojian Liu, Fangfang Lv, Xiaonan Hong, Shaoli Song, Junning Cao
Publikováno v:
Journal of International Medical Research, Vol 50 (2022)
Objective Primary mediastinal B-cell lymphoma (PMBCL) lacks standard treatment regimens. This study aimed to identify the disease’s clinical features and prognostic factors. Methods This retrospective study included 56 patients with PMBCL. Patient
Externí odkaz:
https://doaj.org/article/8d502fb73da54d5e92466b499a22dfb0
Autor:
Lale Kostakoglu, Federico Mattiello, Maurizio Martelli, Laurie H. Sehn, David Belada, Chiara Ghiggi, Neil Chua, Eva González-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Christopher Bolen, Andrea Knapp, Gila Sellam, Tina Nielsen, Deniz Sahin, Umberto Vitolo, Marek Trněný
Publikováno v:
Haematologica, Vol 107, Iss 7 (2021)
This retrospective analysis of the phase III GOYA study investigated the prognostic value of baseline metabolic tumor volume parameters and maximum standardized uptake values for overall and progression-free survival (PFS) in treatment-naïve diffuse
Externí odkaz:
https://doaj.org/article/62cf82718d3a48d2a7f753b32e69d5d4